Last Updated : April 15, 2025
Details
FilesGeneric Name:
risperidone
Project Status:
Active
Therapeutic Area:
Schizophrenia, adults
Manufacturer:
Bausch Health, Canada Inc.
Call for patient/clinician input open:
Brand Name:
Okedi
Project Line:
Reimbursement Review
Project Number:
SR0879-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of schizophrenia in adults.
Submission Type:
Initial
Fee Schedule:
Schedule C
Indications:
For the treatment of schizophrenia in adults.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | February 06, 2025 |
|---|---|
| Call for patient/clinician input closed | March 31, 2025 |
| Submission received | March 21, 2025 |
| Submission accepted | April 04, 2025 |
| Review initiated | April 07, 2025 |
| Draft CADTH review report(s) provided to sponsor for comment | June 23, 2025 |
| Deadline for sponsors comments | July 03, 2025 |
| CDA-AMC review report(s) and responses to comments provided to sponsor | August 15, 2025 |
| Expert committee meeting (initial) | August 27, 2025 |
| Draft recommendation issued to sponsor | September 09, 2025 To September 11, 2025 |
| Draft recommendation posted for stakeholder feedback | September 18, 2025 |
| End of feedback period | October 03, 2025 |
Files
Last Updated : April 15, 2025